Form 4: Anika Therapeutics Director Susan Vogt Reports Acquisition and Disposal of Common Stock

Director Susan Vogt reports acquiring and disposing of Anika Therapeutics common stock on July 9, 2024, according to a Form 4 filing.

Summary

• On July 9, 2024, Susan Vogt, a director of Anika Therapeutics, Inc., engaged in transactions involving the company's common stock.
• Vogt acquired 5,771 shares of common stock and disposed of 36,049 shares.
• Following these transactions, Vogt beneficially owns 36,049 shares of Anika Therapeutics common stock.
• The acquired shares represent restricted stock units (RSUs) that vest in full on the earlier of the 2025 annual meeting or July 9, 2025.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's important for investors to monitor such filings to understand the sentiment and actions of key company personnel.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company directors as an indicator of confidence in the company's prospects.

Key Dates